Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 10-Oct-24 8:38 PM View:  | Kintz Samuel President and CEO Director | Enliven Therapeutics, Inc. (ELVN) | 09-Oct-24 | Sale (Planned) | 16,710 | $28.15 | $470,405.00 | (2%) 1.02M to 1.0M | |
| 10-Oct-24 8:39 PM View: | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Enliven Therapeutics, Inc. (ELVN) | 09-Oct-24 | Sale (Planned) | 37,878 | $28.16 | $1,066,560.00 | (4%) 1.05M to 1.02M | |
| 10-Oct-24 8:36 PM View: | Ballal Rahul D. Director | Enliven Therapeutics, Inc. (ELVN) | 08-Oct-24 | Planned Option Sale | 10,420 | $28.17 | $293,557.00 | (32%) 32.76K to 22.34K | |
| 10-Oct-24 8:39 PM View: | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Enliven Therapeutics, Inc. (ELVN) | 08-Oct-24 | Private Sale (Planned) | 13,267 | $27.97 | $371,024.00 | (1%) 1.07M to 1.05M | |
| 10-Oct-24 8:38 PM View: | Kintz Samuel President and CEO Director | Enliven Therapeutics, Inc. (ELVN) | 08-Oct-24 | Private Sale (Planned) | 13,267 | $27.96 | $370,929.00 | (1%) 1.03M to 1.02M | |
| 10-Oct-24 8:36 PM View: | Ballal Rahul D. Director | Enliven Therapeutics, Inc. (ELVN) | 08-Oct-24 | Option Exercise | 10,420 | $14.10 | $146,925.00 | 47% 22.34K to 32.76K | |
| 08-Oct-24 6:57 PM View: | Kintz Samuel President and CEO Director | Enliven Therapeutics, Inc. (ELVN) | 07-Oct-24 | Sale (Planned) | 2,730 | $27.50 | $75,075.00 | (< 1%) 1.04M to 1.03M | |
| 08-Oct-24 6:56 PM View: | Hohl Benjamin Chief Financial Officer | Enliven Therapeutics, Inc. (ELVN) | 07-Oct-24 | Planned Option Sale | 1,270 | $27.51 | $34,935.30 | (100%) 1.27K to 0 | |
| 08-Oct-24 6:56 PM View: | Hohl Benjamin Chief Financial Officer | Enliven Therapeutics, Inc. (ELVN) | 07-Oct-24 | Option Exercise | 1,270 | $2.48 | $3,149.60 | 100% 0 to 1.27K | |
| 08-Oct-24 6:58 PM View: | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Enliven Therapeutics, Inc. (ELVN) | 07-Oct-24 | Sale (Planned) | 2,707 | $27.61 | $74,727.00 | (< 1%) 1.07M to 1.07M | |
| 08-Oct-24 6:57 PM View: | Kintz Samuel President and CEO Director | Enliven Therapeutics, Inc. (ELVN) | 04-Oct-24 | Private Sale (Planned) | 12,206 | $27.51 | $335,792.00 | (1%) 1.05M to 1.04M | |
| 08-Oct-24 6:56 PM View: | Hohl Benjamin Chief Financial Officer | Enliven Therapeutics, Inc. (ELVN) | 04-Oct-24 | Planned Option Sale | 10,218 | $27.51 | $281,079.00 | (100%) 10.22K to 0 | |
| 08-Oct-24 6:54 PM View: | Heyman Richard A. Director | Enliven Therapeutics, Inc. (ELVN) | 04-Oct-24 | Private Sale (Planned) | 2,825 | $27.51 | $77,703.60 | (1%) 193.91K to 191.09K | |
| 08-Oct-24 6:56 PM View: | Hohl Benjamin Chief Financial Officer | Enliven Therapeutics, Inc. (ELVN) | 04-Oct-24 | Option Exercise | 10,218 | $2.48 | $25,340.60 | 100% 0 to 10.22K | |
| 08-Oct-24 6:58 PM View: | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Enliven Therapeutics, Inc. (ELVN) | 04-Oct-24 | Private Sale (Planned) | 7,522 | $27.51 | $206,937.00 | (< 1%) 1.08M to 1.07M | |
| 01-Oct-24 7:53 PM View: | Hohl Benjamin Chief Financial Officer | Enliven Therapeutics, Inc. (ELVN) | 30-Sep-24 | Option Exercise | 2,000 | $2.48 | $4,960.00 | 100% 0 to 2.0K | |
| 01-Oct-24 7:53 PM View: | Hohl Benjamin Chief Financial Officer | Enliven Therapeutics, Inc. (ELVN) | 30-Sep-24 | Planned Option Sale | 2,000 | $25.33 | $50,667.60 | (100%) 2.0K to 0 | |
| 01-Oct-24 7:53 PM View: | Hohl Benjamin Chief Financial Officer | Enliven Therapeutics, Inc. (ELVN) | 27-Sep-24 | Planned Option Sale | 4,250 | $24.27 | $103,161.00 | (100%) 4.25K to 0 | |
| 01-Oct-24 7:53 PM View: | Hohl Benjamin Chief Financial Officer | Enliven Therapeutics, Inc. (ELVN) | 27-Sep-24 | Option Exercise | 4,250 | $2.48 | $10,540.00 | 100% 0 to 4.25K | |
| 18-Sep-24 4:17 PM View: | Heyman Richard A. Director | Enliven Therapeutics, Inc. (ELVN) | 16-Sep-24 | Private Sale (Planned) | 1,270 | $22.41 | $28,458.20 | (< 1%) 195.7K to 194.43K | |
| 03-Sep-24 5:43 PM View: | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Enliven Therapeutics, Inc. (ELVN) | 29-Aug-24 | Private Sale (Planned) | 12,000 | $22.49 | $269,841.00 | (1%) 1.09M to 1.08M | |
| 29-Aug-24 6:36 PM View: | Hohl Benjamin Chief Financial Officer | Enliven Therapeutics, Inc. (ELVN) | 27-Aug-24 | Planned Option Sale | 4,250 | $22.54 | $95,781.80 | (100%) 4.25K to 0 | |
| 29-Aug-24 6:36 PM View: | Hohl Benjamin Chief Financial Officer | Enliven Therapeutics, Inc. (ELVN) | 27-Aug-24 | Option Exercise | 4,250 | $2.48 | $10,540.00 | 100% 0 to 4.25K | |
| 28-Aug-24 7:48 PM View: | Kintz Samuel President and CEO Director | Enliven Therapeutics, Inc. (ELVN) | 26-Aug-24 | Private Sale (Planned) | 12,000 | $22.89 | $274,718.00 | (1%) 1.06M to 1.05M | |
| 02-Aug-24 7:23 PM View: | Hohl Benjamin Chief Financial Officer | Enliven Therapeutics, Inc. (ELVN) | 31-Jul-24 | Planned Option Sale | 991 | $27.53 | $27,280.90 | (100%) 0.99K to 0 | |
| 02-Aug-24 7:22 PM View: | Heyman Richard A. Director | Enliven Therapeutics, Inc. (ELVN) | 31-Jul-24 | Private Sale (Planned) | 1,702 | $27.51 | $46,815.00 | (< 1%) 199.32K to 197.62K | |
| 02-Aug-24 7:25 PM View: | Kintz Samuel President and CEO Director | Enliven Therapeutics, Inc. (ELVN) | 31-Jul-24 | Private Sale (Planned) | 2,270 | $27.56 | $62,555.10 | (< 1%) 1.06M to 1.06M | |
| 02-Aug-24 7:23 PM View: | Hohl Benjamin Chief Financial Officer | Enliven Therapeutics, Inc. (ELVN) | 31-Jul-24 | Option Exercise | 991 | $2.48 | $2,457.68 | 100% 0 to 0.99K | |
| 02-Aug-24 7:22 PM View: | Heyman Richard A. Director | Enliven Therapeutics, Inc. (ELVN) | 31-Jul-24 | Sale (Planned) | 649 | $27.50 | $17,847.50 | (< 1%) 197.62K to 196.97K | |
| 02-Aug-24 7:26 PM View: | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Enliven Therapeutics, Inc. (ELVN) | 31-Jul-24 | Private Sale (Planned) | 3,099 | $27.56 | $85,399.50 | (< 1%) 1.09M to 1.09M | |
| 31-Jul-24 7:33 PM View: | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Enliven Therapeutics, Inc. (ELVN) | 29-Jul-24 | Private Sale (Planned) | 12,000 | $26.70 | $320,378.00 | (1%) 1.11M to 1.09M | |
| 31-Jul-24 7:31 PM View: | Hohl Benjamin Chief Financial Officer | Enliven Therapeutics, Inc. (ELVN) | 29-Jul-24 | Planned Option Sale | 5,250 | $26.68 | $140,052.00 | (100%) 5.25K to 0 | |
| 31-Jul-24 7:31 PM View: | Hohl Benjamin Chief Financial Officer | Enliven Therapeutics, Inc. (ELVN) | 29-Jul-24 | Option Exercise | 5,250 | $2.48 | $13,020.00 | 100% 0 to 5.25K | |
| 29-Jul-24 5:39 PM View: | Kintz Samuel President and CEO Director | Enliven Therapeutics, Inc. (ELVN) | 25-Jul-24 | Private Sale (Planned) | 12,000 | $24.92 | $299,073.00 | (< 1%) 1.25M to 1.24M | |
| 16-Jul-24 5:37 PM View: | Patel Anish Chief Operating Officer | Enliven Therapeutics, Inc. (ELVN) | 16-Jul-24 | Sale (Planned) | 1,547 | $25.01 | $38,692.20 | (< 1%) 345.57K to 344.03K | |
| 16-Jul-24 5:37 PM View: | Patel Anish Chief Operating Officer | Enliven Therapeutics, Inc. (ELVN) | 15-Jul-24 | Sale (Planned) | 30,978 | $25.05 | $776,039.00 | (8%) 376.55K to 345.57K | |
| 17-Jul-24 7:25 PM View: | Heyman Richard A. Director | Enliven Therapeutics, Inc. (ELVN) | 15-Jul-24 | Private Sale (Planned) | 1,270 | $24.80 | $31,496.80 | (< 1%) 200.59K to 199.32K | |
| 16-Jul-24 5:34 PM View: | Hohl Benjamin Chief Financial Officer | Enliven Therapeutics, Inc. (ELVN) | 12-Jul-24 | Planned Option Sale | 3,000 | $25.07 | $75,195.00 | (100%) 3.0K to 0 | |
| 16-Jul-24 5:34 PM View: | Hohl Benjamin Chief Financial Officer | Enliven Therapeutics, Inc. (ELVN) | 12-Jul-24 | Option Exercise | 3,000 | $2.48 | $7,440.00 | 100% 0 to 3.0K | |
| 16-Jul-24 5:37 PM View: | Patel Anish Chief Operating Officer | Enliven Therapeutics, Inc. (ELVN) | 12-Jul-24 | Private Sale (Planned) | 17,475 | $25.07 | $438,095.00 | (4%) 394.03K to 376.55K | |
| 03-Jul-24 4:31 PM View: | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Enliven Therapeutics, Inc. (ELVN) | 01-Jul-24 | Private Sale (Planned) | 12,000 | $22.89 | $274,736.00 | (1%) 1.12M to 1.11M | |
| 01-Jul-24 8:03 PM View: | Hohl Benjamin Chief Financial Officer | Enliven Therapeutics, Inc. (ELVN) | 27-Jun-24 | Planned Option Sale | 4,250 | $22.57 | $95,921.50 | (100%) 4.25K to 0 | |
| 01-Jul-24 8:03 PM View: | Hohl Benjamin Chief Financial Officer | Enliven Therapeutics, Inc. (ELVN) | 27-Jun-24 | Option Exercise | 4,250 | $2.48 | $10,540.00 | 100% 0 to 4.25K | |
| 27-Jun-24 4:35 PM View: | Kintz Samuel President and CEO Director | Enliven Therapeutics, Inc. (ELVN) | 25-Jun-24 | Private Sale (Planned) | 12,000 | $21.66 | $259,902.00 | (< 1%) 1.26M to 1.25M | |
| 20-Jun-24 7:20 PM View: | Heyman Richard A. Director | Enliven Therapeutics, Inc. (ELVN) | 17-Jun-24 | Private Sale (Planned) | 1,270 | $21.48 | $27,277.90 | (< 1%) 201.86K to 200.59K | |
| 10-Jun-24 6:46 PM View: | Patel Anish Chief Operating Officer | Enliven Therapeutics, Inc. (ELVN) | 06-Jun-24 | Planned Option Sale | 1,133 | $20.06 | $22,722.40 | (< 1%) 395.16K to 394.03K | |
| 10-Jun-24 6:46 PM View: | Patel Anish Chief Operating Officer | Enliven Therapeutics, Inc. (ELVN) | 06-Jun-24 | Option Exercise | 1,133 | $2.48 | $2,809.84 | < 1% 394.03K to 395.16K | |
| 31-May-24 4:05 PM View: | Lyssikatos Joseph P Chief Scientific Officer Director | Enliven Therapeutics, Inc. (ELVN) | 29-May-24 | Option Exercise | 12,000 | $1.12 | $13,440.00 | 1% 1.12M to 1.13M | |
| 31-May-24 4:05 PM View: | Lyssikatos Joseph P Chief Scientific Officer Director | Enliven Therapeutics, Inc. (ELVN) | 29-May-24 | Planned Option Sale | 12,000 | $21.73 | $260,800.00 | (1%) 1.13M to 1.12M | |
| 30-May-24 5:56 PM View: | Kintz Samuel President and CEO Director | Enliven Therapeutics, Inc. (ELVN) | 28-May-24 | Planned Option Sale | 12,000 | $23.18 | $278,210.00 | (< 1%) 1.28M to 1.26M |
